Dong, Yaa-HuiYaa-HuiDongWu, Jo-HsuanJo-HsuanWuCHIA-HSUIN CHANGJOU-WEI LINWu, Li-ChiuLi-ChiuWuToh, SengweeSengweeToh2022-09-152022-09-1520220277-0008https://scholars.lib.ntu.edu.tw/handle/123456789/620550Clinical trials have suggested that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may be associated with a higher risk of biliary-related diseases in patients with type 2 diabetes. Limited real-world studies have examined the comparative biliary safety of GLP-1RAs versus other antihyperglycemic drugs. We aimed to estimate the comparative risk of biliary-related diseases between GLP-1RAs and sodium glucose cotransporter 2 inhibitors (SGLT2is), which are indicated for patients with similar diabetes severity in Taiwan.enacute cholangitis; acute cholecystitis; biliary-related diseases; cholecystectomy; choledocholithiasis; cohort study; glucagon-like peptide-1 receptor agonists; pharmacoepidemiology; sodium glucose cotransporter 2 inhibitors; type 2 diabetes[SDGs]SDG3journal article10.1002/phar.2688355087022-s2.0-85131520217WOS:000799423500001https://api.elsevier.com/content/abstract/scopus_id/85131520217